^(153)Sm-EDTMP致血液学毒性的多因素分析

Multi-factor analysis on events related to hematological toxicity in ^(153)Sm-EDTMP palliative therapy for skeletal metastases

目的探讨153Sm-乙二胺四甲撑膦酸(153Sm-EDTMP)治疗导致白细胞、血小板降低发生的相关因素。方法回顾性地整理206例153Sm-EDTMP治疗后患者的资料,运用Logistic回归对数据进行单因素和多因素分析,对有意义的指标进行分析。结果单因素分析结果表明:153Sm-EDTMP治疗后,血液学毒性的发生与患者的年龄、骨转移灶数目、治疗前化疗史、同时进行外放疗、治疗次数有关;多因素分析结果显示,治疗前化疗史、同时进行外放疗、治疗次数等因素与血液学毒性产生与否有关;治疗前靠药物维持正常血象者也易出现血液学毒性。结论153Sm-EDTMP治疗后血液学毒性的发生与几个因素有关,对有这些因素的患者,应特别注意治疗后血象的变化。

Objective To investigate the clinical factors related to hematological toxicity induced by intravenous samarium-153 ethylenediaminetetramethylene phosphonic acid（^153Sm-EDTMP） treatment. Methods A total of 206 patients with bony metastases treated with ^153Sm-EDTMP were retrospectively analyzed. Logistic regression （SPSS 10.0 for Windows ） and correlation analysis were used to evaluate the factors concerned. Results Age of the patient, number of bone metastatic lesion, chemotherapy before ^153Sm-EDTMP therapy, concurrent radiotherapy and repeat-times of ^153Sm-EDTMP treatments were found the individual factors related to hematological toxicity. Chemotherapy before ^153Sm-EDTMP, concurrent radiotherapy, medication for normal blood counting and repeat-times of ^153Sm-EDTMP treatments were the hematological toxicity factors in multi-factor analysis. Conclusion In ^153Sm-EDTMP therapy, several factors were found related to hematological toxicity suggesting more attention be paid to the change of blood cell counting after the palliative therapy.